Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine tumours, current aspects and new perspectives
Open Access
- 2 March 2010
- journal article
- review article
- Published by Springer Nature in Journal of Experimental & Clinical Cancer Research
- Vol. 29 (1) , 19
Abstract
Gastroenteropancreatic neuroendocrine tumours (GEP NETs) are rare tumours that present many clinical features.Keywords
This publication has 114 references indexed in Scilit:
- The role of somatostatin analogues in the treatment of neuroendocrine tumoursMolecular and Cellular Endocrinology, 2008
- Gastroenteropancreatic neuroendocrine tumoursThe Lancet Oncology, 2008
- Role of somatostatin analogs in the clinical management of non-neuroendocrine solid tumorsAnti-Cancer Drugs, 2006
- Future Aspects of Somatostatin- Receptor-Mediated TherapyNeuroendocrinology, 2004
- Gastrinomas: Advances in Diagnosis and ManagementNeuroendocrinology, 2004
- Effect of Somatostatin and Octreotide on Proliferation and Vascular Endothelial Growth Factor Secretion from Murine Endothelial Cell Line (HECa10) CultureBiochemical and Biophysical Research Communications, 2000
- The Glucagonoma Syndrome Clinical and Pathologic Features in 21 PatientsMedicine, 1996
- Metabolic remission with octreotide in patients with insulinomaJournal of Internal Medicine, 1994
- Octreotide and interferon alfa: A new combination for the treatment of malignant carcinoid tumoursEuropean Journal of Cancer, 1992
- SMS 201–995: A very potent and selective octapeptide analogue of somatostatin with prolonged actionLife Sciences, 1982